Bristol-Myers Squibb Co (BMY) : Partner Investment Management reduced its stake in Bristol-Myers Squibb Co by 29.1% during the most recent quarter end. The investment management company now holds a total of 34,687 shares of Bristol-Myers Squibb Co which is valued at $2,103,073 after selling 14,235 shares in Bristol-Myers Squibb Co , the firm said in a disclosure report filed with the SEC on Aug 15, 2016.Bristol-Myers Squibb Co makes up approximately 3.79% of Partner Investment Management’s portfolio.
Other Hedge Funds, Including , Cornerstone Advisory Llp reduced its stake in BMY by selling 26 shares or 0.4% in the most recent quarter. The Hedge Fund company now holds 6,504 shares of BMY which is valued at $394,338. Bristol-Myers Squibb Co makes up approx 0.32% of Cornerstone Advisory Llp’s portfolio.Roanoke Asset Management Corp Ny reduced its stake in BMY by selling 274 shares or 0.4% in the most recent quarter. The Hedge Fund company now holds 69,005 shares of BMY which is valued at $5,161,574. Bristol-Myers Squibb Co makes up approx 2.27% of Roanoke Asset Management Corp Ny’s portfolio.Rhenman Partners Asset Management Ab reduced its stake in BMY by selling 5,000 shares or 3.52% in the most recent quarter. The Hedge Fund company now holds 137,000 shares of BMY which is valued at $10,247,600. Bristol-Myers Squibb Co makes up approx 1.64% of Rhenman Partners Asset Management Ab’s portfolio.Private Wealth Partners boosted its stake in BMY in the latest quarter, The investment management firm added 2,350 additional shares and now holds a total of 7,750 shares of Bristol-Myers Squibb Co which is valued at $592,643. Bristol-Myers Squibb Co makes up approx 0.14% of Private Wealth Partners’s portfolio.
Bristol-Myers Squibb Co closed down -0.63 points or -1.10% at $56.76 with 1,28,73,853 shares getting traded on Thursday. Post opening the session at $57.6, the shares hit an intraday low of $56.49 and an intraday high of $57.62 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.
On the company’s financial health, Bristol-Myers Squibb Co reported $0.69 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on Jul 28, 2016. Analyst had a consensus of $0.66. The company had revenue of $4881.00 million for the quarter, compared to analysts expectations of $4657.63 million. The company’s revenue was up 17.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.53 EPS.
Investors should note that on Aug 3, 2016, Bristol-Myers Squibb Co announced a cash dividend of $0.3800. The company’s management has announced Oct 5, 2016 as the ex-dividend date and fixed the record date on Oct 7, 2016. The payable date has been fixed on Nov 1, 2016.
Many Wall Street Analysts have commented on Bristol-Myers Squibb Co. Bristol-Myers Squibb Co was Downgraded by Berenberg to ” Hold” on Aug 11, 2016. Credit Suisse Downgraded Bristol-Myers Squibb Co on Aug 8, 2016 to ” Neutral”, Price Target of the shares are set at $63.Shares were Reiterated by Deutsche Bank on Aug 8, 2016 to “Hold” and Lowered the Price Target to $ 62 from a previous price target of $68 .
Bristol-Myers Squibb Company (BMS) is engaged in the discovery development licensing manufacturing marketing distribution and sale of biopharmaceutical products across the world. The Company’s products are sold to wholesalers retail pharmacies hospitals government entities and the medical profession. The Company manufactures its products in the United States Puerto Rico and in six foreign countries. The Company promotes the use of its products directly to healthcare professionals and providers such as doctors nurse practitioners physician assistants pharmacists technologists hospitals Pharmacy Benefit Managers (PBMs) and Managed Care Organizations (MCOs). It also provides information about the use of its products to consumers in the United States through direct-to-consumer print radio television and digital advertising and promotion. In addition the Company holds rights to F001287 which is a preclinical small-molecule IDO1-inhibitor.